GlassScriptPhysician profile
Faisal Chaudhry
NPI 1366559668
$8,546.05
in general payments reported to CMS, 2019-2025
12 companies · $402 in 2025
The $402 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,146 · 2020: $593 · 2021: $1,252 · 2022: $1,709 · 2023: $1,659 · 2024: $1,785 · 2025: $402.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,846.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,846.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $2,414.87 | 2019-2025 | Invega Sustenna, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $2,368.26 | 2019-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Teva Pharmaceuticals USA, INC. | $1,164.56 | 2021-2024 | Uzedy, Austedo, Austedo Xr |
| Janssen Biotech, INC. | $929.36 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $655.85 | 2022-2024 | Ingrezza |
| Alkermes, INC. | $439.17 | 2019-2024 | Lybalvi, Aristada |
| Indivior INC. | $145.41 | 2020-2021 | |
| Genentech USA, INC. | $139.80 | 2023-2025 | Actemra |
| Abbvie INC. | $111.36 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $104.45 | 2024 | |
| Lundbeck LLC | $52.63 | 2024 | Abilify Maintena |
| Astrazeneca Pharmaceuticals LP | $20.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Faisal Chaudhry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.